LIVE Day One – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8, 2019
Reporter: Aviva Lev-Ari, PhD, RN
www.worldmedicalinnovation.org
The Forum will focus on patient interactions across care settings, and the role technology and data can play in advancing knowledge discovery and care delivery. The agenda can be found here.
https://worldmedicalinnovation.org/agenda/
Leaders in Pharmaceutical Business Intelligence (LPBI) Group
represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media
3.1.4 LIVE Day One – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8, 2019, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
Monday, April 8, 2019
Bayer Ballroom
First Look: Round 1
Nine rapid fire presentations on the applications of AI in Clinical Care
To view speakers and topics, click here.
Henry Chueh, MD
Director, MGH Lab of Computer Science, MGH; Assistant Professor, Medicine, HMS
Dxplain: Expanding diagnostic horizons
Synho Do, MD
Director, Laboratory of Medical Imaging and Computation (LMIC), MGH; Assistant Professor, HMS
Leveraging a Deep-Learning Algorithm for the Detection of Acute Intracranial Hemorrhage
Laura Germine, PhD
Director, Laboratory for Brain and Cognitive Health Technology, McLean; Assistant Professor, Psychiatry, HMS
The Next Generation of Cognitive and Behavioral Assessment
Satrajit Ghosh, PhD
Research Associate, MEE; Principal Research Scientist, MIT; Assistant Professor, Otolaryngology, HMS
Assistive Intelligent Technologies for Brain Health
Chris Sidey-Gibbons, PhD
Co-Director, PROVE Center, BH; Member of Faculty, HMS
Three Computational Techniques and One Tool to Bring the Patient Voice into Care
Xudong Huang, PhD
Co-Director, Neurochemistry Laboratory; MGH; Associate Professor, Psychiatry, HMS
Leveraging Artificial Intelligence for Brain Drug Discovery
Tina Kapur, PhD
Executive Director, Image-Guided Therapy, BH; Assistant Professor, Radiology, HMS
Using AI to Better Visualize Needles in Ultrasound-Guided Liver Biopsies
Bharti Khurana, MD
Director, Emergency Musculoskeletal Radiology, BH; Assistant Professor, HMS
Vesela Kovacheva, MD, PhD
Attending Anesthesiologist, BH; Instructor, Anesthesiology, HMS
Harnessing the Power of Machine Learning to Automate Drug Infusions in the OR and ICU
Constance Lehman, MD, PhD
Chief, Breast Imaging Division, MGH; Professor of Radiology, HMS
AI-Based Care Delivery: A New Paradigm for Curing Cancer
Lisa Nickerson, PhD
Director, Applied Neuroimaging Statistics Lab, McLean; Assistant Professor, HMS
Using Digital Phenotyping and Machine Learning to Forecast, Detect, and Prevent Drug Overdose Deaths
Federico Parisi, PhD
Research Fellow, Wyss Institute for Biologically Inspired Engineering, SRN
Mobile Health Technologies for Monitoring Motor Fluctuations in Patients with Parkinson’s Disease
Stuart Pomerantz, MD
Director, Neuro-CT, Neuroradiology, MGH; Instructor, HMS
AI-Powered Diagnostic Reporting for Spinal MRI of Degenerative Disease
Sandro Santagata, MD, PhD
Assistant Professor, Pathology, BH, HMS
Joseph Schwab, MD
Chief, Orthopaedic Spine Surgery, MGH; Associate Professor, HMS
Artificial Intelligence for Diagnosis and Management in Spine Surgery
Hiroyuki Yoshida, PhD
Director, 3D Imaging Research, MGH; Associate Professor, Radiology, HMS
Nazlee Zebardast, MD
Instructor, Ophthalmology, MEE, HMS
Li Zhou, MD, PhD
Associate Professor/Lead Investigator, BH; Associate Professor, HMS
Machine Learning and NLP to Track Disease Progression and Predict Health Outcomes
Bayer Ballroom
First Look: Round 2
Nine rapid fire presentations on the applications of AI in Clinical Care
To view speakers and topics, click here.
Discovery Café Sessions
Applying AI to Save Lives During the Opioid Crisis
The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die nationally every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, AI is being harnessed to develop new tools that can help alleviate this national crisis. This session will discuss AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, and also data privacy concerns.
Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS
Bob Burgin, CEO, Amplifire Healthcare Alliance
Carm Huntress, CEO, RxRevu Inc
Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS
Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BH; Assistant Professor, HMS
Community Hospitals: Key Component in Healthcare Transformation
Community hospitals are the largest sources of patient care in the U.S. As such, they represent a frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the distinctions from academic medical centers? This session will address these and other topics that impact community hospitals.
Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS
Fabien Beckers, PhD, CEO, Arterys
Joanna Geisinger, CEO, TORq Interface
John Miller, MD, Director, Retinal Imaging, MEE; Assistant Professor, Ophthalmology, HMS
Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS
Tal Wenderow, CEO, Beyond Verbal
Digital Management of Diabetes
Across the spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with an artificial pancreas on the horizon. This session will focus on these areas and clinical use cases that highlight the value of AI.
Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS
Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BH; Lecturer, HMS
Michael Meissner, PhD, CTO and VP, MED, Sanofi
Joshua Riff, MD, CEO, Onduo
Marie Schiller, VP, Connected Care and Insulins Product Development and Site Head, Cambridge Innovation Center, Eli Lilly
AI and Its Impact on the Future of Emergency Care
There are over 136 million Emergency Department visits annually in the U.S. providing 24/7 unscheduled treatment for problems from minor illness to life threatening traumatic injuries. Emergency department care teams provide high quality, safe care in an efficient fashion. In this session, we consider the future of AI in emergency care from the initial decision to seek emergency care, to diagnostic processes within the ED and final disposition decision.. From chat bots for patient triage, telehealth for patient visits to machine learning outcome prediction, we will consider how these novel technologies will impact emergency care delivery.
Moderator: Adam Landman, MD, VP and CIO, BH; Associate Professor of Emergency Medicine, HMS
Peter Chai, MD, Assistant Professor, Emergency Medicine, BH, HMS
Emily Hayden, MD, Attending Physician, Emergency Medicine, MGH; Instructor, Surgery, HMS
Kohei Hasegawa, MD, Attending Physician, Emergency Medicine, MGH; Associate Professor, Emergency Medicine, HMS
Sean Kelly, MD, CMO, Imprivata; Assistant Professor, Emergency Medicine, HMS
Bijoy Sagar, VP, Chief Digital Technology Officer, Stryker
Mental Health, Smartphone Apps and the Promise of AI
Patients can face significant barriers when it comes to accessing high-quality, evidence-based treatment for mental illness. AI-enabled technologies, including smartphone-based tools, that may help close this treatment gap for patients worldwide. This session will focus on efforts to develop smartphone apps and other tools, including those designed to help predict patients’ moods and provide cognitive behavioral therapy.
Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS
Jennifer Gentile, PsyD, SVP, US Clinical Operations, Ieso Digital Health
Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry and Medicine, HMS
Christopher Molaro, CEO, Neuroflow
David Silbersweig, MD, Chairman, Department of Psychiatry, BH; Stanley Cobb Professor of Psychiatry, HMS
Jeremy Sohn, VP, Global Head of Digital Business Development and Licensing , Novartis
From Startup to Impact (Pharma and Diagnostics)
This session will introduce you to five leading start-up companies who will each share their respective impact in the pharmaceutical and diagnostic realms in 10-minute pitches.
Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS
Moderator: James Nicholls, Managing Director, Fitzroy Health
Sarah Beeby, EVP, GM Lifesciences, Clinithink
Charles Cadieu, PhD, CEO, Bay Labs
JB Michel, PhD, SVP Data Science & GM USA, BenevolentAI
Art Papier, MD, CEO, VisualDx
Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc
Bayer Ballroom
Bayer Ballroom
AI Strategy: AI from the Top
As the potential of AI comes into clearer view, many academic medical centers are taking notice and crafting institutional strategies for incorporating AI into clinical practice. But where are the most meaningful opportunities? What are the biggest challenges? And, importantly, will patient care be noticeably different — better, more available, and/or less costly?
Bayer Ballroom
1:1 Fireside Chat: Jensen Huang, CEO, NVIDIA
Bayer Ballroom
Bayer Ballroom
Real World Evidence and Trial Optimization in the AI Era
AI is a tool for conducting faster, more efficient clinical trials. Panelists will discuss how AI-enabled methods can further adaptive trial capabilities, trial design and trial management.
Bayer Ballroom
AI Driven Value-Based Care
As providers embrace value-based approaches, the demands of clinical data collection, assessment, and information-sharing loom large. In this data-driven environment, clinicians must sift through ever-growing pools of information that can exceed the limits of human capability. An assortment of AI-based solutions is now emerging that may offer some relief. Panelists will discuss how these approaches are helping to support better, more personalized care, and the challenges faced by clinicians and managers for effective adoption.
Bayer Ballroom
Cardiovascular Care: Reinvented Through AI
Cardiovascular diseases remain the leading cause of death worldwide and an expense, making this area ripe for AI-enabled innovations. Teams are pursuing a range of AI-based tools in cardiovascular medicine: including AI-powered drug discovery and diagnostics to automated cardiac image analyses and AI-guided care delivery pathways. Panelists will discuss where AI is having a sizeable impact. The discussion will also include the perspectives of a patient who benefited from AI-enabled cardiovascular care.
Bayer Ballroom


Leave a Reply